Concepts (268)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 46 | 2024 | 895 | 6.770 |
Why?
|
| Transgender Persons | 19 | 2024 | 116 | 5.400 |
Why?
|
| Homosexuality, Male | 26 | 2022 | 317 | 3.380 |
Why?
|
| Sexual and Gender Minorities | 12 | 2022 | 228 | 2.660 |
Why?
|
| Pre-Exposure Prophylaxis | 10 | 2024 | 164 | 2.250 |
Why?
|
| Sexual Partners | 10 | 2021 | 104 | 1.860 |
Why?
|
| Chicago | 26 | 2024 | 1466 | 1.680 |
Why?
|
| Substance-Related Disorders | 6 | 2021 | 424 | 1.490 |
Why?
|
| Unsafe Sex | 8 | 2024 | 45 | 1.390 |
Why?
|
| Substance Abuse, Intravenous | 3 | 2021 | 62 | 1.360 |
Why?
|
| Sexually Transmitted Diseases | 4 | 2022 | 102 | 1.290 |
Why?
|
| Crime | 2 | 2020 | 37 | 1.280 |
Why?
|
| Sexual Behavior | 15 | 2024 | 320 | 1.260 |
Why?
|
| Residence Characteristics | 3 | 2020 | 204 | 1.240 |
Why?
|
| Risk-Taking | 12 | 2021 | 158 | 1.220 |
Why?
|
| Social Support | 4 | 2020 | 222 | 1.190 |
Why?
|
| Antiretroviral Therapy, Highly Active | 3 | 2017 | 74 | 1.130 |
Why?
|
| Gonorrhea | 3 | 2016 | 23 | 1.050 |
Why?
|
| Adolescent | 34 | 2024 | 9504 | 1.050 |
Why?
|
| Chlamydia Infections | 3 | 2016 | 32 | 1.050 |
Why?
|
| Young Adult | 32 | 2024 | 6624 | 1.040 |
Why?
|
| Social Stigma | 4 | 2023 | 76 | 1.010 |
Why?
|
| Anti-HIV Agents | 7 | 2022 | 173 | 0.980 |
Why?
|
| Viral Load | 5 | 2021 | 148 | 0.880 |
Why?
|
| Adult | 40 | 2024 | 27532 | 0.790 |
Why?
|
| Risk Reduction Behavior | 5 | 2018 | 97 | 0.770 |
Why?
|
| Continuity of Patient Care | 3 | 2020 | 176 | 0.750 |
Why?
|
| Exposure to Violence | 2 | 2018 | 12 | 0.730 |
Why?
|
| Male | 50 | 2024 | 43925 | 0.730 |
Why?
|
| Condoms | 2 | 2024 | 39 | 0.710 |
Why?
|
| Anti-Retroviral Agents | 1 | 2020 | 31 | 0.690 |
Why?
|
| Health Knowledge, Attitudes, Practice | 7 | 2024 | 542 | 0.690 |
Why?
|
| Criminals | 1 | 2020 | 33 | 0.680 |
Why?
|
| Female | 51 | 2024 | 47893 | 0.670 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 91 | 0.660 |
Why?
|
| Humans | 67 | 2024 | 92337 | 0.640 |
Why?
|
| Heterosexuality | 2 | 2015 | 20 | 0.600 |
Why?
|
| Patient Acceptance of Health Care | 4 | 2017 | 276 | 0.600 |
Why?
|
| Mass Screening | 4 | 2020 | 675 | 0.600 |
Why?
|
| Urban Population | 3 | 2018 | 229 | 0.590 |
Why?
|
| Bisexuality | 7 | 2016 | 35 | 0.580 |
Why?
|
| Social Identification | 1 | 2017 | 27 | 0.540 |
Why?
|
| Hepatitis B Antibodies | 1 | 2016 | 16 | 0.520 |
Why?
|
| Stress, Psychological | 5 | 2021 | 329 | 0.520 |
Why?
|
| Ambulatory Care Facilities | 2 | 2015 | 115 | 0.510 |
Why?
|
| Intimate Partner Violence | 1 | 2016 | 28 | 0.500 |
Why?
|
| Hepatitis B | 1 | 2016 | 79 | 0.490 |
Why?
|
| Hospitalization | 2 | 2022 | 927 | 0.490 |
Why?
|
| Social Networking | 3 | 2021 | 78 | 0.480 |
Why?
|
| Hepatitis C | 1 | 2016 | 179 | 0.440 |
Why?
|
| Prisons | 1 | 2014 | 12 | 0.440 |
Why?
|
| Opioid-Related Disorders | 3 | 2024 | 202 | 0.440 |
Why?
|
| Homosexuality, Female | 5 | 2014 | 16 | 0.430 |
Why?
|
| Cross-Sectional Studies | 12 | 2023 | 1774 | 0.430 |
Why?
|
| Health Care Surveys | 2 | 2016 | 286 | 0.430 |
Why?
|
| AIDS Serodiagnosis | 1 | 2013 | 27 | 0.430 |
Why?
|
| Prisoners | 1 | 2014 | 46 | 0.420 |
Why?
|
| Sexually Transmitted Diseases, Bacterial | 1 | 2012 | 3 | 0.410 |
Why?
|
| HIV Seronegativity | 1 | 2012 | 13 | 0.410 |
Why?
|
| Disease Progression | 2 | 2016 | 1503 | 0.400 |
Why?
|
| CD4 Lymphocyte Count | 3 | 2017 | 70 | 0.390 |
Why?
|
| Syphilis, Latent | 1 | 2011 | 1 | 0.360 |
Why?
|
| Health Personnel | 1 | 2013 | 224 | 0.360 |
Why?
|
| Alcohol Drinking | 2 | 2016 | 278 | 0.360 |
Why?
|
| Socioeconomic Factors | 7 | 2020 | 611 | 0.360 |
Why?
|
| HIV Seropositivity | 1 | 2011 | 52 | 0.350 |
Why?
|
| Logistic Models | 3 | 2024 | 1239 | 0.320 |
Why?
|
| Middle Aged | 18 | 2024 | 27030 | 0.320 |
Why?
|
| Central Nervous System Stimulants | 2 | 2022 | 223 | 0.320 |
Why?
|
| HIV-1 | 2 | 2021 | 161 | 0.290 |
Why?
|
| Peer Group | 4 | 2017 | 89 | 0.290 |
Why?
|
| Longitudinal Studies | 4 | 2020 | 1119 | 0.280 |
Why?
|
| Naloxone | 2 | 2024 | 69 | 0.270 |
Why?
|
| Electronic Health Records | 1 | 2011 | 364 | 0.270 |
Why?
|
| Cohort Studies | 4 | 2021 | 2978 | 0.270 |
Why?
|
| Sex Factors | 4 | 2019 | 1095 | 0.260 |
Why?
|
| Risk Factors | 6 | 2019 | 5704 | 0.260 |
Why?
|
| Program Evaluation | 3 | 2024 | 315 | 0.250 |
Why?
|
| Coinfection | 2 | 2016 | 63 | 0.240 |
Why?
|
| Glycogen | 2 | 2016 | 60 | 0.240 |
Why?
|
| Prevalence | 4 | 2018 | 1294 | 0.230 |
Why?
|
| Medication Adherence | 2 | 2016 | 147 | 0.220 |
Why?
|
| Adolescent Behavior | 2 | 2016 | 110 | 0.220 |
Why?
|
| Vagina | 2 | 2016 | 176 | 0.220 |
Why?
|
| Viremia | 2 | 2021 | 49 | 0.220 |
Why?
|
| Narcotic Antagonists | 1 | 2024 | 165 | 0.210 |
Why?
|
| Health Promotion | 2 | 2014 | 168 | 0.200 |
Why?
|
| Focus Groups | 3 | 2023 | 186 | 0.190 |
Why?
|
| Syphilis | 2 | 2014 | 34 | 0.190 |
Why?
|
| United States | 8 | 2022 | 7348 | 0.190 |
Why?
|
| Sexual Health | 1 | 2022 | 19 | 0.190 |
Why?
|
| Hand Disinfection | 1 | 2021 | 18 | 0.190 |
Why?
|
| Vulnerable Populations | 2 | 2020 | 84 | 0.190 |
Why?
|
| Aged | 8 | 2021 | 19943 | 0.190 |
Why?
|
| Sexuality | 1 | 2021 | 41 | 0.180 |
Why?
|
| Needle Sharing | 1 | 2021 | 15 | 0.180 |
Why?
|
| Needle-Exchange Programs | 1 | 2021 | 18 | 0.180 |
Why?
|
| Masks | 1 | 2021 | 30 | 0.180 |
Why?
|
| Incidence | 5 | 2022 | 1661 | 0.180 |
Why?
|
| Social Environment | 2 | 2020 | 187 | 0.180 |
Why?
|
| Geography | 2 | 2021 | 234 | 0.180 |
Why?
|
| Contact Tracing | 1 | 2021 | 29 | 0.180 |
Why?
|
| Methamphetamine | 1 | 2022 | 93 | 0.180 |
Why?
|
| Attitude of Health Personnel | 2 | 2016 | 657 | 0.170 |
Why?
|
| Women's Health | 3 | 2018 | 105 | 0.170 |
Why?
|
| Psychotherapy, Brief | 1 | 2020 | 13 | 0.170 |
Why?
|
| Vaginosis, Bacterial | 2 | 2016 | 8 | 0.160 |
Why?
|
| Population Surveillance | 2 | 2020 | 214 | 0.160 |
Why?
|
| Internal-External Control | 1 | 2019 | 45 | 0.160 |
Why?
|
| Forecasting | 1 | 2020 | 311 | 0.160 |
Why?
|
| Juvenile Delinquency | 1 | 2019 | 26 | 0.160 |
Why?
|
| Decision Making | 2 | 2015 | 680 | 0.160 |
Why?
|
| Qualitative Research | 2 | 2023 | 325 | 0.160 |
Why?
|
| Mental Health | 1 | 2020 | 184 | 0.150 |
Why?
|
| Marijuana Smoking | 1 | 2018 | 27 | 0.150 |
Why?
|
| Urban Health | 2 | 2015 | 56 | 0.150 |
Why?
|
| Internet | 2 | 2021 | 331 | 0.150 |
Why?
|
| Suburban Population | 1 | 2018 | 6 | 0.150 |
Why?
|
| Lactobacillus | 2 | 2016 | 22 | 0.150 |
Why?
|
| Mother-Child Relations | 1 | 2018 | 28 | 0.150 |
Why?
|
| Alcoholism | 1 | 2020 | 185 | 0.140 |
Why?
|
| Drug Users | 1 | 2018 | 26 | 0.140 |
Why?
|
| Proportional Hazards Models | 2 | 2017 | 871 | 0.140 |
Why?
|
| Racism | 1 | 2019 | 96 | 0.140 |
Why?
|
| New York City | 1 | 2017 | 60 | 0.140 |
Why?
|
| Analgesics, Opioid | 1 | 2022 | 472 | 0.140 |
Why?
|
| Population Dynamics | 1 | 2018 | 142 | 0.140 |
Why?
|
| Illinois | 3 | 2024 | 503 | 0.130 |
Why?
|
| Mothers | 1 | 2018 | 149 | 0.130 |
Why?
|
| Hepatitis B Core Antigens | 1 | 2016 | 10 | 0.130 |
Why?
|
| Marijuana Abuse | 1 | 2016 | 29 | 0.130 |
Why?
|
| Reminder Systems | 1 | 2016 | 19 | 0.130 |
Why?
|
| Evidence-Based Practice | 1 | 2016 | 49 | 0.130 |
Why?
|
| Body Fluids | 1 | 2016 | 34 | 0.130 |
Why?
|
| Cocaine-Related Disorders | 1 | 2016 | 36 | 0.130 |
Why?
|
| Text Messaging | 1 | 2016 | 31 | 0.130 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 1 | 2015 | 21 | 0.120 |
Why?
|
| Progesterone | 1 | 2016 | 110 | 0.120 |
Why?
|
| Violence | 2 | 2016 | 149 | 0.120 |
Why?
|
| DNA, Viral | 1 | 2016 | 253 | 0.120 |
Why?
|
| Minority Groups | 2 | 2014 | 150 | 0.120 |
Why?
|
| Secondary Prevention | 1 | 2016 | 172 | 0.120 |
Why?
|
| Cytomegalovirus | 1 | 2015 | 85 | 0.120 |
Why?
|
| Estrogens | 1 | 2016 | 200 | 0.120 |
Why?
|
| Biomarkers | 3 | 2016 | 1850 | 0.120 |
Why?
|
| Public Health Surveillance | 1 | 2015 | 24 | 0.120 |
Why?
|
| Trust | 1 | 2015 | 98 | 0.120 |
Why?
|
| Cytomegalovirus Infections | 1 | 2015 | 153 | 0.110 |
Why?
|
| Syphilis Serodiagnosis | 1 | 2014 | 9 | 0.110 |
Why?
|
| Glomerular Filtration Rate | 1 | 2015 | 280 | 0.110 |
Why?
|
| Treponema pallidum | 1 | 2014 | 8 | 0.110 |
Why?
|
| Social Marketing | 1 | 2014 | 11 | 0.110 |
Why?
|
| Chlamydia trachomatis | 1 | 2014 | 15 | 0.110 |
Why?
|
| Neisseria gonorrhoeae | 1 | 2014 | 17 | 0.110 |
Why?
|
| Mass Media | 1 | 2014 | 27 | 0.110 |
Why?
|
| Smoking Prevention | 1 | 2014 | 46 | 0.110 |
Why?
|
| Psychology, Adolescent | 1 | 2013 | 29 | 0.110 |
Why?
|
| Antibodies, Bacterial | 1 | 2014 | 103 | 0.110 |
Why?
|
| Smoking Cessation | 2 | 2014 | 265 | 0.110 |
Why?
|
| Awareness | 1 | 2014 | 89 | 0.110 |
Why?
|
| Patient Compliance | 1 | 2015 | 236 | 0.110 |
Why?
|
| HIV Serosorting | 1 | 2012 | 3 | 0.100 |
Why?
|
| Unemployment | 1 | 2013 | 11 | 0.100 |
Why?
|
| Health Services Accessibility | 2 | 2017 | 451 | 0.100 |
Why?
|
| Self Disclosure | 1 | 2012 | 32 | 0.100 |
Why?
|
| Health Education | 1 | 2013 | 105 | 0.100 |
Why?
|
| Attitude to Health | 1 | 2014 | 221 | 0.100 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2015 | 237 | 0.100 |
Why?
|
| Quality of Life | 1 | 2020 | 1744 | 0.100 |
Why?
|
| Adaptation, Psychological | 1 | 2013 | 169 | 0.090 |
Why?
|
| Depression | 1 | 2016 | 526 | 0.090 |
Why?
|
| Case-Control Studies | 1 | 2016 | 1902 | 0.090 |
Why?
|
| Informed Consent | 1 | 2014 | 278 | 0.090 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2013 | 498 | 0.090 |
Why?
|
| Odds Ratio | 1 | 2013 | 694 | 0.090 |
Why?
|
| Urban Health Services | 1 | 2011 | 44 | 0.090 |
Why?
|
| Aging | 1 | 2015 | 738 | 0.090 |
Why?
|
| Surveys and Questionnaires | 4 | 2021 | 2729 | 0.090 |
Why?
|
| Smoking | 2 | 2014 | 640 | 0.090 |
Why?
|
| Kidney | 1 | 2015 | 1145 | 0.080 |
Why?
|
| Pregnancy | 2 | 2016 | 3110 | 0.080 |
Why?
|
| Retrospective Studies | 3 | 2014 | 9703 | 0.080 |
Why?
|
| Texas | 2 | 2022 | 126 | 0.080 |
Why?
|
| Aged, 80 and over | 1 | 2020 | 6916 | 0.080 |
Why?
|
| Regression Analysis | 1 | 2011 | 595 | 0.080 |
Why?
|
| Microbiota | 1 | 2014 | 412 | 0.080 |
Why?
|
| Health Behavior | 2 | 2021 | 185 | 0.070 |
Why?
|
| Cluster Analysis | 2 | 2021 | 376 | 0.070 |
Why?
|
| Attitude | 2 | 2022 | 129 | 0.070 |
Why?
|
| Practice Guidelines as Topic | 1 | 2013 | 1079 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2021 | 900 | 0.060 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 2016 | 501 | 0.060 |
Why?
|
| Follow-Up Studies | 1 | 2011 | 3775 | 0.050 |
Why?
|
| Drug Overdose | 1 | 2024 | 78 | 0.050 |
Why?
|
| HIV | 1 | 2022 | 48 | 0.050 |
Why?
|
| Interviews as Topic | 1 | 2023 | 351 | 0.050 |
Why?
|
| Greece | 1 | 2022 | 19 | 0.050 |
Why?
|
| Stakeholder Participation | 1 | 2022 | 22 | 0.050 |
Why?
|
| Feasibility Studies | 2 | 2014 | 800 | 0.050 |
Why?
|
| Infectious Disease Medicine | 1 | 2021 | 7 | 0.050 |
Why?
|
| Policy | 1 | 2022 | 39 | 0.050 |
Why?
|
| Time Factors | 1 | 2011 | 5430 | 0.050 |
Why?
|
| Criminal Law | 1 | 2021 | 11 | 0.050 |
Why?
|
| Communicable Disease Control | 1 | 2021 | 51 | 0.050 |
Why?
|
| Sex Workers | 1 | 2021 | 9 | 0.040 |
Why?
|
| Louisiana | 1 | 2020 | 18 | 0.040 |
Why?
|
| Probability | 1 | 2021 | 357 | 0.040 |
Why?
|
| Risk Assessment | 2 | 2020 | 2369 | 0.040 |
Why?
|
| Cities | 1 | 2020 | 52 | 0.040 |
Why?
|
| Poverty | 1 | 2021 | 189 | 0.040 |
Why?
|
| Social Determinants of Health | 1 | 2021 | 105 | 0.040 |
Why?
|
| Psychological Theory | 1 | 2020 | 23 | 0.040 |
Why?
|
| Multivariate Analysis | 1 | 2021 | 996 | 0.040 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2019 | 120 | 0.030 |
Why?
|
| Chile | 1 | 2016 | 7 | 0.030 |
Why?
|
| Sex Work | 1 | 2016 | 12 | 0.030 |
Why?
|
| Microbiological Techniques | 1 | 2016 | 24 | 0.030 |
Why?
|
| School Teachers | 1 | 2016 | 2 | 0.030 |
Why?
|
| Baltimore | 1 | 2016 | 41 | 0.030 |
Why?
|
| Premenopause | 1 | 2016 | 57 | 0.030 |
Why?
|
| Florida | 1 | 2016 | 60 | 0.030 |
Why?
|
| Research Design | 1 | 2020 | 600 | 0.030 |
Why?
|
| Raltegravir Potassium | 1 | 2015 | 2 | 0.030 |
Why?
|
| Self Efficacy | 1 | 2016 | 60 | 0.030 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2015 | 23 | 0.030 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2015 | 32 | 0.030 |
Why?
|
| Proteinuria | 1 | 2015 | 69 | 0.030 |
Why?
|
| Health Care Costs | 1 | 2017 | 248 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2020 | 8740 | 0.030 |
Why?
|
| Demography | 1 | 2015 | 186 | 0.030 |
Why?
|
| Fluorescent Treponemal Antibody-Absorption Test | 1 | 2014 | 1 | 0.030 |
Why?
|
| Pain Measurement | 1 | 2016 | 360 | 0.030 |
Why?
|
| Linear Models | 1 | 2015 | 427 | 0.030 |
Why?
|
| Medical Audit | 1 | 2014 | 39 | 0.030 |
Why?
|
| Receptors, Cell Surface | 1 | 2015 | 291 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2015 | 272 | 0.030 |
Why?
|
| Luminescent Measurements | 1 | 2014 | 62 | 0.030 |
Why?
|
| Social Norms | 1 | 2013 | 14 | 0.030 |
Why?
|
| Antibodies, Viral | 1 | 2015 | 302 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2014 | 299 | 0.030 |
Why?
|
| Transcultural Nursing | 1 | 2013 | 2 | 0.030 |
Why?
|
| Midwestern United States | 1 | 2013 | 85 | 0.030 |
Why?
|
| Reference Standards | 1 | 2014 | 144 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2015 | 473 | 0.030 |
Why?
|
| Nursing Methodology Research | 1 | 2013 | 11 | 0.030 |
Why?
|
| Interferon-gamma | 1 | 2015 | 453 | 0.030 |
Why?
|
| Immunoglobulin G | 1 | 2015 | 460 | 0.030 |
Why?
|
| Cultural Competency | 1 | 2013 | 21 | 0.030 |
Why?
|
| Human Rights | 1 | 2013 | 19 | 0.030 |
Why?
|
| Inservice Training | 1 | 2013 | 38 | 0.030 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2014 | 259 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 866 | 0.030 |
Why?
|
| Motivation | 1 | 2016 | 310 | 0.030 |
Why?
|
| Models, Psychological | 1 | 2013 | 161 | 0.030 |
Why?
|
| ROC Curve | 1 | 2015 | 785 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2018 | 1150 | 0.020 |
Why?
|
| Aggression | 1 | 2016 | 324 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2014 | 901 | 0.020 |
Why?
|
| Patient Education as Topic | 1 | 2014 | 370 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2014 | 874 | 0.020 |
Why?
|
| Base Sequence | 1 | 2014 | 2317 | 0.020 |
Why?
|
| Child | 1 | 2022 | 7334 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2013 | 578 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 2009 | 0.020 |
Why?
|
| Inflammation | 1 | 2015 | 1025 | 0.020 |
Why?
|
| Phylogeny | 1 | 2015 | 1228 | 0.020 |
Why?
|
| Curriculum | 1 | 2013 | 581 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2015 | 4468 | 0.020 |
Why?
|